Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Glycotope, a Germany-based developer of antibodies targeting glycostructures on cell surfaces, has recruited first patient in the Phase I trial evaluating TrasGEX.
Subscribe to our email newsletter
The trial aims to evaluate the safety and tolerability of TrasGEX, a glycooptimized HER2 biobetter antibody.
TrasGEX is developed using GlycoExpress, the company’s development and production platform based on glycoengineered human cell lines for biopharmaceuticals with fully human and optimized glycosylation.
Glycotope CEO, CSO and founder Steffen Goletz said after CetuGEX and PankoMab-GEX, TrasGEX is their third anti-cancer antibody which entered clinical trials in time.
"Our glycooptimized Follicle-Stimulating Hormone FSH-GEX has already completed clinical Phase Ia with very exciting results," Goletz said.